COMPASS PATHWAYS PLC (CMPS) Operating Margin
- Operating margin · 12 months: Value (m); Formula and calculation Operating income / revenue. Period ending 2026-06-30..
Operating margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Operating margin · 12 months | (m) | Operating income / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating income | -181.76M USD | Operating Income (Loss) |
| Revenue | (m) | |
| Cost of products and services | (m) | |
| Research and development | 112.89M USD | Research and Development Expense |
| Selling, general and administration | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Operating income (USD) | Revenue (USD) | Cost of products and services (USD) | Research and development (USD) | Selling, general and administration (USD) | Operating margin |
|---|---|---|---|---|---|---|
| 2026-06-30 | $-181.76M | (m) | (m) | $112.89M | (m) | (m) |
| 2026-03-31 | $-172.32M | (m) | (m) | $114.04M | (m) | (m) |
| 2025-12-31 | $-179.04M | (m) | (m) | $118.44M | (m) | (m) |
| 2025-09-30 | $-181.50M | (m) | (m) | $120.67M | (m) | (m) |
| 2025-06-30 | $-188.86M | (m) | (m) | $126.27M | (m) | (m) |
| 2025-03-31 | $-189.25M | (m) | (m) | $125.02M | (m) | (m) |
| 2024-12-31 | $-178.21M | (m) | (m) | $119.04M | (m) | (m) |
| 2024-09-30 | $-168.20M | (m) | (m) | $114.04M | (m) | (m) |
| 2024-06-30 | $-154.36M | (m) | (m) | $102.64M | (m) | (m) |
| 2024-03-31 | $-143.70M | (m) | (m) | $93.38M | (m) | (m) |
| 2023-12-31 | $-136.92M | (m) | (m) | $87.52M | (m) | (m) |
| 2023-09-30 | $-130.71M | (m) | (m) | $80.17M | (m) | (m) |
| 2023-06-30 | $-122.18M | (m) | (m) | $72.62M | (m) | (m) |
| 2023-03-31 | $-116.77M | (m) | (m) | $68.73M | (m) | (m) |
| 2022-12-31 | $-110.40M | (m) | (m) | $65.05M | (m) | (m) |
| 2022-09-30 | $-106.53M | (m) | (m) | $58.85M | (m) | (m) |
| 2022-06-30 | $-102.77M | (m) | (m) | $57.07M | (m) | (m) |
| 2022-03-31 | $-95.04M | (m) | (m) | $52.51M | (m) | (m) |
| 2021-12-31 | $-83.22M | (m) | (m) | $44.03M | (m) | (m) |
| 2021-09-30 | $-66.42M | (m) | (m) | $34.98M | (m) | (m) |
| 2021-06-30 | $-58.13M | (m) | (m) | $29.66M | (m) | (m) |
| 2021-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-12-31 | $-51.39M | (m) | (m) | $23.37M | (m) | (m) |
| 2020-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-12-31 | $-21.18M | (m) | (m) | $12.56M | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ANI PHARMACEUTICALS INC (ANIP) | United States | $1.810B | 18.77 |
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |